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The aim of this review was to summarize current knowledge on the correlation between depressive symptoms with a syndrome
calledpartialandrogendeﬁciencyoftheagingmale(PADAM)andonthepotentialbeneﬁtsoftestosterone(T)treatmentonmood.
Despite, the causative nature of the relationship between low T levels and depression is uncertain, many hypogonadal men suﬀer
from depression and vice versa several depressed patients are aﬀected by hypogonadism. Supplementation with testosterone failed
to show sound evidence of eﬀectiveness in the treatment of depression. Nevertheless, testosterone supplementation has proved
to be eﬀective on some domains signiﬁcant for the quality of life of aged patients with PADAM (sexual function and cognitive
functions, muscular strengths).
1.Introduction
Testosterone deﬁciency or hypotestosteronemia is a widely
recognized hormonal alteration associated with male aging
[1–3]. Its prevalence may be as high as 30% in men aged 40–
79 years [4, 5], and in up to 12% the hypotestosteronemia it
can be associated with clinical symptoms [5]. Nevertheless,
diﬀerent levels of testosterone (T) could be associated with
the presence of speciﬁc clinical symptoms [6, 7].
The joint consensus of International Society of Androl-
ogy,theInternationalSocietyfortheStudyoftheAgingMale
(ISSAM) and the European Association of Urology prepared
a set of recommendations speciﬁcally on the Investigation,
treatment, and monitoring of late-onset hypogonadism in
males [8, 9]. Laboratory diagnosis of hypogonadism is
based on the measurement of serum total testosterone (TT).
Although there is no uniformly accepted threshold level for
T in older men, TT levels above 350ng/dL are considered
normal and do not require substitution therapy, while TT
levels below 230ng/dL usually beneﬁt from testosterone
treatment. When TT level is between 230 and 350ng/dL, it
may be useful to calculate free testosterone (FT), particularly
in obese men. FT level below 65pg/mL suggests that
testosterone treatment is needed [10, 11].
In2010,theEndocrineSocietypublishedclinicalpractice
guidelines for testosterone therapy in adult men with andro-
gen deﬁciency syndrome [12]. The members of the working
group agreed that because the normative ranges for TT and
FT in healthy young men vary among laboratories and assays
(lower TT limits: 280–300ng/dL; lower FT limits: 5–9pg/
mL) [13], clinicians should use the lower limit of normal
range for healthy young men established in their laboratory.
Members of the working group disagreed on T concen-
trations below which testosterone supplementation should
be oﬀered to older men with symptomatic hypogonadism.
Some members of the working group recommended T sup-
plementation in older men with TT level below 300ng/dL,
because this is the threshold at which older men have2 International Journal of Endocrinology
symptoms that might be attributable to low testosterone;
others recommended T supplementation only in those with
TT level below 200ng/dL, because higher pretreatment T
values are associated with lower beneﬁcial eﬀects of T
therapy.
Age-related serum testosterone decline is caused by dif-
ferent simultaneous mechanisms, such as primary structural
gonadal impairment, age-related degenerative modiﬁcations
of the pituitary gland, deﬁcits of the neurohypothalamic
system, and primary peripheral metabolic abnormalities
such as the age-associated increase in the concentration
of serum sex hormone binding globulin (SHBG), with a
consequent decrease in FT [3].
It is controversial whether aging is to be considered as
the only variable linked to age-related T decline [14, 15]:
several factors do seem to interfere in diﬀerent ways with
T metabolism, like genetic factors [16], chronic diseases
[17–19], chronic medications [20], obesity [7, 21, 22], and
lifestyle factors [23, 24].
Despite the fact that many men with low testosterone
levels are asymptomatic [25], many others have a partial,
gradual, and variable decline in T associated with various
clinical symptoms, described as a syndrome called partial
androgen deﬁciency of the aging male (PADAM) [26].
PADAM is characterized by sexual, somatic, and behavioral
symptoms, with insidious onset and slow progression [27]:
diminished sexual desire and erectile quality, particularly
nocturnal erections [28, 29]; decrease in lean body mass,
with associated diminution in muscle volume and strength;
increase in visceral fat [30–32], decrease in bone mineral
density, resulting in osteoporosis [33]; reduction in body
hair and skin alterations [34]; weakness, fatigue, depression,
lack of motivation and energy, lower psychological vitality,
anxiety, irritability, insomnia, decreased work and sport per-
formances; diﬃculty in concentrating, memory impairment,
and low dominance [35–41].
In the Endocrine Society Guidelines symptoms are sepa-
rated into two groups, more speciﬁc symptoms and signs of
hypogonadism (incomplete or delayed sexual development,
sexual disorders, breast discomfort, gynecomastia, loss of
body [axillary and pubic] hair, reduced shaving, very small
or shrinking testes, inability to father children, low or zero
spermcount,heightloss,lowtraumafracture,lowbonemin-
eral density, hot ﬂushes, and sweats) and less speciﬁc symp-
toms (decreased energy, motivation, initiative, self-conﬁ-
dence, feeling sad or blue, depressed mood, dysthymia, poor
concentration and memory, sleep disturbance, increased
sleepiness, mild anemia, reduced muscle bulk and strength,
increased body fat, body mass index, and diminished phys-
ical or work performance) [12]. Serum T concentration has
to be measured in patients with the more speciﬁc symptoms
of hypogonadism and considered in those who report the
less speciﬁc symptoms. The diagnosis of hypogonadism is
possible when serum T level is below lower limits, and rever-
sible illness, drugs, and nutritional deﬁciency have been
excluded.
PADAM as a clinical entity is still controversial, because
it is very diﬃcult to distinguish to what extent the symptoms
attributed to PADAM are due to the natural and unavoidable
consequencesofagingandhowmuchtoandrogendeﬁciency
[37, 42, 43].
Behavioral aspects of PADAM may overlap with signs
of depression. For example, McIntyre et al. [44] consid-
ered that reduction in physiologically active bioavailable
testosterone (BT) concentration is a vulnerability factor for
depressive symptoms in middle-aged depressed men. The
authors assessed and compared TT and BT levels in two
groupsofmiddle-agedmen(40–65years),untreatedsubjects
meeting DSM-IV-TR (Diagnostic and Statistical Manual of
Mental Disorders—4th edition, text revised) [45] criteria
for a major depressive episode (N = 44), and a matched
nondepressed control group (N = 50). Depressed men had
lower mean BT levels and TT levels than the control group.
Biochemical hypogonadism (i.e., BT level ≤70ng/dL or TT
level ≤350ng/dL) was also more prevalent in depressed men
than in nondepressed controls (34% versus 6%; 61% versus
14%, resp.).
Thus, the aim of this review was to summarize current
knowledge on depressive symptoms correlated with PADAM
and on the potential beneﬁts of T treatment on mood.
2. Methods
In order to provide a critical review of the association of
PADAM and depression in older males, we performed a
PubMed search to identify all papers published in English
peer-reviewed journals between 1980 and 2012. The search
string was androgen deﬁciency OR testosterone deﬁciency
OR hypogonadism OR testosterone treatment OR testos-
terone supplementation AND depress∗.
We limited the search to articles reporting data for male
aged 45+ years old. All English full-text articles reporting
original data about the main topic were included. The
reference lists of the articles included in the review were also
manually checked to retrieve other relevant studies.
3. Results
3.1. T Levels and Depression. Epidemiological and clinical
studies of the connection between age-related low T levels
andareducedfeelingofwell-being,withunusualanxietyand
irritability,nervousness,moodswings,andadepressivestate,
have produced mixed results [46–63] (see Tables 1 and 2).
Positive results were reported by Hintikka et al. [47]w h o
examined associations between hypogonadism (laboratory
diagnosis was based on FT level <4.6ng/dL), erectile dys-
function,sexualdesire,andlong-termandcurrentdepressive
symptoms in a population-based sample of Finnish middle-
aged men. The inclusion criteria for this study were based on
self-reportedadversementalsymptomsprevailingatbaseline
and at the 3-year followup. At 7 years from the baseline,
men who reported long-term adverse mental symptoms had
higher depression but lower FT levels than asymptomatic
men. Furthermore, depression correlated negatively with FT
(rho = −0.20; P<0.05) in the entire sample.
The Rancho Bernardo Study examined the association













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.6 International Journal of Endocrinology
m e na g e d5 0t o8 9y e a r s( m e a na g e7 0 . 2y e a r s )d u r i n ga
period of 4 years [64]. In that study, BT levels decreased
with age and were signiﬁcantly and inversely associated with
Beck Depression Inventory (BDI) scores [65], indicating
more depressive symptoms associated with lower BT levels.
There was a graded stepwise decrease in BT, with a parallel
increasing level of depressed mood; in addition, BT levels
were17%lowerinmenwithcategoricallydeﬁneddepression
than in controls.
Lee et al. [66] investigated the PADAM in a community
sample of 311 Chinese men (aged 40–80) attending a family
medicine clinic in Hong Kong. A total of 87.8% of the
sample was screened PADAM positive using the ADAM
questionnaire. PADAM-positive individuals were found to
have poorer quality of life, higher depression and anxiety,
even after adjusting for age and number of current diseases.
I nah i s t o r i c a lc o h o r ts t u d y ,t h eV e t e r a n sA ﬀairs Puget
Sound Health Care System carried out on 278 men aged
45 years and older without previous depressive diagnosis,
hypogonadal men with TT levels of 200ng/dL or less
(compared to eugonadal men) showed an approximate 4-
fold increase in the risk of incident depression in the 2-year
followup [67]. The risk of depression was inversely related to
T levels, with statistically signiﬁcant ﬁndings observed at T
levels lower than 280ng/dL.
Inasampleof32subjectswithdysthymicdisorder(mean
age 70.5, SD 5.8, range = 60–82 years), Seidman et al.
[62] found that most elderly men with dysthymic disorder
had TT levels in the hypogonadal range (i.e., ≤300ng/dL).
Furthermore, their TT levels were lower than in patients
with MDD or healthy controls. The authors hypothesized
that dysthymic disorder in elderly men may be related to
HPG axis hypofunction. This association is believed to be
the result of either chronic depression leading to HPG axis
blunting, or to HPG axis hypofunctioning leading to low-
grade depression [68].
Furthermore, there is some evidence that, compared
with controls, T secretion is blunted among older men
with severe major depressive disorder (MDD), it appears to
normalize after major depressive episode remission [60, 61].
A signiﬁcant increase in depression during the androgen
deprivation treatment period, and a tendency to decline after
chemical castration was discontinued has been observed in
eugonadal men at risk for prostate cancer who are treated
with androgen blockade therapy [69].
No association between depression and T level has been
reported in the Massachusetts Male Aging Study, a cross-
sectional, population-based multidisciplinary survey of
1,709 normally aging men (aged 39–70 years) [70]. Partially
positive results were also reported more recently in the
Tromso Study [56]. In this study, lower testosterone levels
were associated with subthreshold symptoms of anxiety
and depression. The Veterans’ Experience Study [71], which
investigated a sample of 4,393 veterans who served the U.S.
military (mean age 37 years), found small but signiﬁcant
associations between depression and T Level (r = 0.04;P<
0.01). However, in this latter study, the authors pointed out
that the relationship between T level and depression may
actually be curvilinear [71].
The causative nature of the relationship between low
T levels and depression is uncertain. For example, inves-
tigators of the Massachusetts Male Aging Study found a
signiﬁcant interaction between polymorphic CAG repeats
sequence encoding a variable-length glutamine chain in
the N-terminal transactivation domain of an androgen
receptor genetic polymorphism protein, testosterone level,
and depression [72]. The CAG repeat length appears to have
modulatory eﬀects on androgen action [73, 74], and the
associations between depression and testosterone concen-
tration may be mediated by diﬀerent androgen sensitivity.
The psychiatric eﬀects of T may be also mediated through
modulation of brain monoamine levels and, in particular,
of the serotonergic function [75, 76]. In animal models, T
increases cortical serotonin 2A receptor binding densities
[77]and,inhumans,corticalserotonin2Areceptorsdecrease
with depression and aging [78].
3.2. T Treatment of Depression in Older Men. Although the
practice of hormone replacement therapy began as long ago
as the 18th century, with the use of extractions of repro-
ductive organs of animals to treat a variety of ailments or
to enhance the capacity for enjoyment of work and sexual
activity [79–81], the role of T therapy for middle-aged and
older men with depression is still uncertain (see Tables
3 and 4). T replacement in hypogonadal males generally
decreases anger, nervousness, irritability and anxiety [35],
andconsistentlyleadstoincreasedsexualinterestandactivity
([82, 83], see [84] for negative results).
In a randomized, placebo-controlled, double-blind,
phase III trial (ClinicalTrials.gov identiﬁer: NCT00696748),
184 men suﬀering from both the metabolic syndrome and
hypogonadism were treated for 30 weeks with either parent-
eral testosterone undecanoate (TU; 1,000mg IMTU) or
placebo injections [85]. Depression was assessed at the base-
line and at 18 and 30 weeks with the BDI. At baseline,
depression signiﬁcantly correlated with the total testosterone
level (r =− 0.16;P = 0.03). When comparing the changes
over time in patients treated with TU versus the placebo
group, there was a signiﬁcant improvement in depression
(mean diﬀerence versus placebo after 30 weeks: −2.5 points;
95% CI: −0.9; −4.1; P = 0.003). Eﬀects were strongest in
menwiththelowestbaselinetotaltestosterone(<222ng/dL).
In a sample of 51 hypogonadal men (aged 22 to 60
years) studied for 60 days, T replacement improved positive
mood parameters, such as energy, well-being and friend-
liness, and decreased negative mood parameters including
anger, nervousness, and irritability [35]. Direct correlations
between serum T and dihydrotestosterone (DHT) with
mood scores were only observed in the baseline period,
when serum androgen levels were below the normal range.
This observation may indicate that it is possible that, once
a minimally adequate serum T/DHT level is achieved by
T replacement therapy, further increases in serum T/DHT
levels do not further contribute to the improvement in mood
variables.Inasubsequenttrial,Wangetal.[82]administered
a transdermal T gel formulation to hypogonadal men (227





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.12 International Journal of Endocrinology
Mood improved and the improvement was maintained with
continued treatment.
Recently, Shores et al. [86] examined the eﬀect of testos-
terone treatment in older, hypogonadal men (50+ years old)
with subthreshold depression in a double-blind random-
ized controlled trial. Participants received either 7.5g of
testosterone gel or placebo gel daily for 12 weeks, followed
by a 12-week open-label extension phase during which
all subjects received 7.5g of testosterone gel. At the end
of the double-blind phase, testosterone-treated men had a
greater reduction in depression (P<0.05) and a higher
remission rate of subthreshold depression (52.9% versus
18.8%, P<0.05) than did placebo-treated men. At the end
oftheopen-labelphase,thetestosteronegrouphadsustained
improvement,whilepatientswhohadreceivedplacebointhe
previous 12 weeks improved, and there were no diﬀerences
between groups on the number of depressive symptoms
reported.
Seidman et al. [87] conducted a six-week double-blind
placebo-controlled clinical trial in 23 men with mid-life
onset male dysthymic disorder and with low or low-normal
testosterone level (TT < 350ng/dL). After the intervention,
the depression decreased signiﬁcantly more in the testos-
terone group than in the placebo group (P<0.01).
However, some studies have shown that, in the short and
long term [88], T replacement is not superior to placebo in
elderly men with low-normal gonadal status, or in men with
the lowest BT levels [89–91].
Androgentreatmentineugonadalmenhasdemonstrated
subtle changes in sexual arousal, cognition, and mood [36],
withasigniﬁcantincreaseinmanicandaggressivesymptoms
[92, 93]. However, two studies failed to observe eﬀects of T
on mood in healthy men with induced hypogonadism who
were given T [94, 95].
To date, little evidence supports the use of androgen
therapy in older depressed men [96]. In a study by Perry
et al. [97], a subgroup of elderly depressed males (aged
70 and over) improved with T therapy. In a study of 15
elderly eugonadal males with major depressive disorder
(MDD, according to the DSM-IV criteria), 5 with early
onset MDD, and 10 with late onset MDD, treatment with T
cypionate(100mg/weekor200mg/weekIMfor6weeks)was
eﬃcacious only in some cases of late-onset depression.
Androgen administration in open and blind clinical
trials to chronically depressed men or to hypogonadal men
with depression refractory to selective serotonin reuptake
inhibitors (SSRIs) improved depressive symptoms. Human
and animal studies have demonstrated that T treatment
may facilitate the antidepressant drug response [98–100].
T augmentation in men with major depression refractory
to SSRIs treatment and low or borderline TT levels (200–
350ng/dL) produced signiﬁcant positive results in short-
term treatment (12 weeks) [98, 101], but doubts arose about
longer-term treatment (20 weeks) [99].
At the present time, available data do not suggest the use
ofTinthetreatmentofdepressioninPADAM.Dataonolder
men suﬀering from depression and PADAM are still few and
inadequate [102], and the current clinical guidelines for men
with low serum T concentration stress that T therapy for
depression is irrelevant [12, 103, 104].
Furthermore, T supplementation may be associated with
some adverse eﬀects, such as erythrocytosis, acne and oily
skin, detection of subclinical prostate cancer, growth of
metastatic prostate cancer, and reduced sperm production
and fertility [12, 104]. Other, uncommon, adverse events
for which there is weak evidence of association with testos-
terone administration are gynecomastia, male pattern bald-
ing (familial), and induction or worsening of obstructive
sleep apnea. Formulation-speciﬁc adverse eﬀects include
ﬂuctuation in mood or libido, pain at injection site, excessive
erythrocytosis (especially in older patients), and coughing
episodes immediately after the intramuscular injection for
intramuscular injections of testosterone enanthate, cypi-
onate, or undecanoate, as well as frequent skin reactions at
application site for transdermal patches, and potential risk
for testosterone transfer to partner or others in close contact
with the individual, and skin irritation for transdermal gel
[12].
4. Discussion
As Western populations represent an aging society with
continuing gains in life expectancy [4], hypogonadism in
older men may have signiﬁcant public health implications
[67, 109, 110]. For example, over the last decade, this has led
toasigniﬁcantmarketgrowthinTtherapiesformen40years
and older [4].
PADAM includes behavioral and depressive symptoms
that vary greatly from individual to individual, being the
result not only of biological and psychosocial changes, but
alsoofpersonal ability toadapt tosuchchanges. The eﬃcacy
of T therapy in the treatment of depression in elderly hypog-
onadal men is inconclusive. Research on T replacement
therapyfordepressivesymptomsofPADAMrevealsthegreat
variability of the results.
Nonetheless,androgenssupplementationmaybeauseful
asadjunctivetherapyindepressedhypogonadalmen.Several
study reported that antidepressants may be associated with
sexual dysfunction in adult patients [111], and up to 20%
of users may suﬀer from sexual dysfunction [112]. Sexual
dysfunction may also be associated with discontinuation of
antidepressants treatment [113]. T treatment may have ben-
eﬁcial eﬀects on sexual functions [83, 89, 94, 103, 114–116].
Recently,Amiazetal.[83]conducteda6-week,double-blind,
placebo-controlled clinical trial of testosterone gel versus
placebo gel in men with MDD who were currently taking a
serotonergicantidepressantandexhibitedloworlow-normal
testosterone level. The results indicated that those taking
testosterone improved in sexual functions as measured
through the International Index of Erectile Function more
than those in the placebo arm. Furthermore, the results
indicated that the improvement in sexual functioning did
not appear to be attributable to improvement in depression.
Ttreatmentma ybeparticularlyusefultoimprov equality
of life in elderly hypogonadal men, because its eﬀect on mus-
cular strength [117–119] and may be on cognitive functions
[57, 120–122].International Journal of Endocrinology 13
However,duetoadverseeﬀectsassociatedwithTtherapy,
pretreatment screening for parameters related to potential
risks of testosterone supplementation is essential. T supple-
mentation is contraindicated in individuals with hematocrit
of 52% and over [123, 124], prostatic carcinoma, an andro-
gen sensitive-tumor, and in cases of mammary carcinoma in
men [12, 103].
In conclusion, despite the causative nature of the rela-
tionship between low T levels and depression is uncertain,
many hypogonadal men suﬀer from depression and vice
versa. Supplementation with testosterone failed to show
sound evidence of eﬀectiveness in the treatment of depres-
sion.Nevertheless,Tsupplementationhasprovedtobeeﬀec-
tive on some domains signiﬁcant for the quality of life of
patients with PADAM. Those eﬀects may partially mediate
the eﬀects on depressive symptomatology reported in some
trials. Thus, the overall improvement in well-being and
health,relatedtothequalityoflifeinagingmaleswithpartial
androgen deﬁciency, may have a positive impact on their
mood.
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